SAN FRANCISCO, Feb. 22, 2017 /PRNewswire/ -- Nektar Therapeutics
(Nasdaq: NKTR) will announce its financial results for the fourth
quarter and year-ended December 31,
2016, on Wednesday, March 1,
2017, after the close of U.S.-based financial markets.
Howard Robin, president and chief
executive officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time (ET)/2:00 p.m. Pacific
Time (PT).
The press release and a live audio-only Webcast of the
conference call can be accessed through a link that is posted on
the home page and Investors section of the Nektar website:
http://www.nektar.com. The web broadcast of the conference call
will be available for replay through Monday,
April 3, 2017.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 75461730 (Nektar Therapeutics is the host)
About Nektar
Nektar Therapeutics has a robust R&D pipeline and
portfolio of approved partnered medicines in oncology, pain,
immunology and other therapeutic areas. In the area of
oncology, Nektar is developing NKTR-214, an
immuno-stimulatory CD122-biased agonist, that is in Phase 1/2
clinical development for patients with solid tumors. ONZEALD™
(etirinotecan pegol), a long-acting topoisomerase I inhibitor, is
being developed for patients with advanced breast cancer and brain
metastases and is partnered with Daiichi Sankyo in Europe. In
the area of pain, Nektar has an exclusive worldwide
license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the
first FDA-approved once-daily oral peripherally-acting
mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with
chronic, non-cancer pain. The product is also approved in
the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. The AstraZeneca agreement also includes
NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE® [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. and Japan for
patients over 12 with hemophilia A. In anti-infectives, the company
has two collaborations with Bayer Healthcare, Cipro Inhale in
Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale
in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in
the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE®, UCB's Cimzia® for Crohn's disease
and rheumatoid arthritis, and Amgen's Neulasta® for
neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE® is a registered trademark of Baxalta Incorporated, a
wholly owned, indirect subsidiary of Shire plc.
Cimzia® is a registered trademark of UCB.
ONZEALD™ is a trademark of Nektar Therapeutics.
Contact:
For Investors and Media:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2016-on-wednesday-march-1-2017-after-close-of-us-based-financial-markets-300412074.html
SOURCE Nektar Therapeutics